IL6 and rheumatoid arthritis: The Id1 can accelerate the formation of new blood vessels in the inflammatory micro-environment by activating the intracellular c-Jun N terminal kinases signaling pathway, promoting FLS proliferation, and inhibiting IL-6 and IL-8 secretion in immune cells, consequently mediating RA pathogenesis [5].